5 mg/ml Augentropfen
Sponsors
Janssen - Cilag International, Inmunotek S.L.
Conditions
EGFR-mutated Advanced or Metastatic Non-small Cell Lung CancerGrass pollen induced allergic rhinitis or rhinoconjunctivitisbirch pollen-induced allergic rhinitis
birch pollen-induced allergic rhinoconjunctivitis
Phase 2
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib
RecruitingCTIS2023-505863-35-00
Start: 2024-03-20Target: 15Updated: 2025-10-27
A prospective, randomized, double-blind, placebo-controlled, multicentre, dose-finding clinical trial with polymerised mannan-conjugated allergoid Dactylis glomerata/Phleum pratense administered subcutaneously to patients with grass pollen-induced allergic rhinitis or rhinoconjunctivitis.
Not yet recruitingCTIS2025-524580-21-00
Target: 450Updated: 2026-05-29